Opportunity Information: Apply for CDC RFA GH15 1630
Apply for CDC RFA GH15 1630
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "Sustained Strengthening of Public Health Laboratory, Transfusion Services, and Health Care Worker Infection Control Practices for Ebola Virus Disease in Liberia" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.318 Protecting and Improving Health Globally Building and Strengthening Public Health Impact, Systems, Capacity and Securit.
- This funding opportunity was created on Mar 26, 2015 and posted on Mar 26, 2015.
- Applicants must submit their applications by Apr 30, 2015 Electronically submitted applications must be submitted no later than 1159 p.m., Eastern Standard Time, on the listed application due date.. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $20,000,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $10,000,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- University of Massachusetts Medical School, Academic Consortium Combating Ebola in Liberia (ACCEL)
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Centers for Disease Control and Prevention (CDC) funding opportunity CDC RFA GH15-1630 focuses on helping Liberia rebuild and harden key parts of its health system after the peak of the Ebola virus disease (EVD) crisis. When the outbreak began, many hospitals and clinics shut down, and even as case counts declined and facilities reopened, the central problem remained the same: routine care could not safely resume without stronger infection control, faster and more reliable diagnostics, and safer, better organized blood transfusion services. The grant is structured as a cooperative agreement, which typically means CDC would remain substantially involved in oversight and technical direction while the recipient carries out day-to-day implementation.
The project is organized around three main components. First, it supports infection prevention and control (IPC) in hospitals and health centers nationwide, reflecting the reality that health care workers were among the most heavily affected groups during the outbreak. The announcement cites more than 360 infections and 170 deaths among Liberian health care workers, emphasizing how quickly Ebola exposure can occur in clinical settings when triage and protective practices break down. This part of the award is intended to deliver comprehensive IPC training, plus ongoing support and monitoring, so staff can consistently identify and manage suspected Ebola cases while also protecting themselves and continuing to treat non-Ebola conditions. The underlying goal is to keep routine services open and safer, rather than having fear of infection or unsafe working conditions disrupt care again.
Second, the award aims to strengthen public health laboratory capacity inside hospital laboratories by supplying equipment and consumables and providing mentoring and training for laboratory technicians. A major operational challenge during the outbreak was that early Ebola symptoms (such as fever, vomiting, and diarrhea) overlap with many common illnesses in Liberia, including malaria and other viral infections, as well as complications of pregnancy. Without dependable diagnostics, patients could be isolated unnecessarily, or true Ebola cases could be missed and continue spreading infection. By expanding capacity for Polymerase Chain Reaction (PCR) testing and other diagnostic methods closer to the point of care, the program is designed to speed up confirmation or rule-out of Ebola and improve diagnosis for other illnesses, which in turn supports better patient management and more effective infection control decisions.
Third, the opportunity includes targeted work to strengthen Liberia's blood transfusion services through training and direct technical assistance focused on blood collection and storage processes. Improving these systems is meant to increase the availability and safety of life-saving transfusions, which are essential for maternal health emergencies, severe anemia (including malaria-related anemia), trauma, and surgical care. In the context of Ebola recovery, stronger transfusion services also contribute to broader health system resilience by making routine and emergency care more dependable and reducing preventable deaths unrelated to Ebola.
From an administrative standpoint, the opportunity was posted March 26, 2015, with an application deadline of April 30, 2015, and an archive date of May 30, 2015. CDC anticipated one award, with an estimated total funding amount of $20,000,000 and an award ceiling of $10,000,000 (award floor listed as $0). There was no cost sharing or matching requirement. Eligibility was limited and specifically identified the University of Massachusetts Medical School and the Academic Consortium Combating Ebola in Liberia (ACCEL). The CFDA listing referenced is 93.318, aligned with global health protection and strengthening public health systems and capacity. The listed point of contact for access issues was Brian Wheeler (BIW8@cdc.gov).
Frequently Asked Questions (FAQs) - CDC RFA GH15-1630
What is CDC RFA GH15-1630 about?
CDC RFA GH15-1630 is a CDC funding opportunity focused on helping Liberia rebuild and strengthen key parts of its health system after the peak of the Ebola virus disease (EVD) crisis. The work centers on making routine health care safer and more reliable by improving infection prevention and control, strengthening diagnostic laboratory capacity, and improving blood transfusion services.
What type of funding mechanism is this?
This opportunity is structured as a cooperative agreement. That typically means CDC remains substantially involved in oversight and technical direction, while the recipient is responsible for day-to-day implementation.
Why was this opportunity created?
During the Ebola outbreak, many hospitals and clinics in Liberia shut down. Even as facilities reopened and case counts declined, routine care could not safely resume without stronger infection control, faster and more reliable diagnostics, and safer, better organized blood transfusion services.
What are the main components of the project?
The project is organized around three components:
- Infection prevention and control (IPC) support in hospitals and health centers nationwide
- Strengthening public health laboratory capacity inside hospital laboratories (including PCR and other diagnostics)
- Strengthening blood transfusion services through training and technical assistance focused on blood collection and storage
What does the infection prevention and control (IPC) component include?
The IPC component is intended to deliver comprehensive IPC training along with ongoing support and monitoring. The goal is to help health care staff consistently identify and manage suspected Ebola cases, protect themselves, and continue treating non-Ebola conditions without major service disruptions.
Why is IPC emphasized in this program?
Health care workers were among the most heavily affected groups during the outbreak. The announcement cites more than 360 infections and 170 deaths among Liberian health care workers, highlighting how quickly Ebola exposure can occur in clinical settings when triage and protective practices break down.
What is the overall goal of the IPC work?
The underlying goal is to keep routine services open and safer, rather than allowing fear of infection or unsafe working conditions to disrupt care again.
What does the laboratory capacity component support?
This component aims to strengthen capacity within hospital laboratories by supplying equipment and consumables and providing mentoring and training for laboratory technicians. A key focus is expanding capacity for PCR testing and other diagnostic methods closer to the point of care.
Why are diagnostics a major focus of this opportunity?
Early Ebola symptoms (such as fever, vomiting, and diarrhea) overlap with many common illnesses in Liberia, including malaria and other viral infections, as well as complications of pregnancy. Without dependable diagnostics, patients could be isolated unnecessarily, or true Ebola cases could be missed and continue spreading infection.
How is improved diagnostics expected to help patient care and Ebola control?
By speeding up confirmation or rule-out of Ebola and improving diagnosis for other illnesses, stronger diagnostics support better patient management and more effective infection control decisions.
What does the blood transfusion services component cover?
The opportunity includes targeted work to strengthen Liberia's blood transfusion services through training and direct technical assistance focused on blood collection and storage processes. The intent is to improve the availability and safety of transfusions.
Why are blood transfusion services included in an Ebola recovery effort?
Safe, reliable transfusion services are essential for maternal health emergencies, severe anemia (including malaria-related anemia), trauma, and surgical care. Strengthening transfusion systems supports broader health system resilience and helps reduce preventable deaths unrelated to Ebola.
When was the opportunity posted, and what were the key dates?
The opportunity was posted March 26, 2015. The application deadline was April 30, 2015, and the archive date was May 30, 2015.
How many awards did CDC anticipate making under this opportunity?
CDC anticipated making one award.
How much funding was available?
The estimated total funding amount was $20,000,000. The award ceiling was $10,000,000. The award floor was listed as $0.
Was cost sharing or matching required?
No. There was no cost sharing or matching requirement.
Who was eligible to apply?
Eligibility was limited. The opportunity specifically identified the University of Massachusetts Medical School and the Academic Consortium Combating Ebola in Liberia (ACCEL).
What CFDA number is referenced for this opportunity?
The CFDA listing referenced is 93.318, aligned with global health protection and strengthening public health systems and capacity.
What kinds of facilities are targeted by the program activities?
Based on the description, activities include hospitals and health centers nationwide for IPC work, and hospital laboratories for laboratory strengthening, along with targeted strengthening of blood transfusion services.
What support does the program provide besides training?
In addition to training, the program description includes ongoing support and monitoring for IPC, and the provision of laboratory equipment and consumables plus mentoring for laboratory technicians. For transfusion services, it includes direct technical assistance focused on blood collection and storage.
Who should be contacted for access issues related to this opportunity?
The listed point of contact for access issues was Brian Wheeler at BIW8@cdc.gov.
Browse more opportunities from the same category: Health
Next opportunity: Limited Competition Informatics, Coordination and Service Center for the Mutant Mouse Resource and Research Centers (U42)
Previous opportunity: Securing the Cities Program
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA GH15 1630
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA GH15 1630) also looked into and applied for these:
| Funding Opportunity |
|---|
| Limited Competition Informatics, Coordination and Service Center for the Mutant Mouse Resource and Research Centers (U42) Apply for PAR 15 156 Funding Number: PAR 15 156 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Using Evidence from Science and Community Practice to Develop Web and other Technology Based Tools for HIV Treatment Service Provider Organizations to Improve Linkage, Retention, and Re Engagement of HIV Positive Persons in Care Apply for CDC RFA PS13 131103CONT15 Funding Number: CDC RFA PS13 131103CONT15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Alcohol Impairment of Immune Function, Host Defense and Tissue Homeostasis (R01) Apply for PA 15 159 Funding Number: PA 15 159 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Minority Serving Institutions (MSIs) Partnerships with Community Based Organizations (CBOs). Short Title MSI CBO Apply for SP 15 004 Funding Number: SP 15 004 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $300,000 |
| Planning Grant for Global Infectious Disease Research Training Program (D71) Apply for PAR 15 160 Funding Number: PAR 15 160 Agency: National Institutes of Health Category: Health Funding Amount: $28,000 |
| Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34) Apply for RFA MH 16 410 Funding Number: RFA MH 16 410 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R21/R33) Apply for RFA MH 16 405 Funding Number: RFA MH 16 405 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Exploratory Clinical Trials of Novel Interventions for Mental Disorders (R33) Apply for RFA MH 16 400 Funding Number: RFA MH 16 400 Agency: National Institutes of Health Category: Health Funding Amount: $2,000,000 |
| Confirmatory Efficacy Clinical Trials of Non Pharmacological Interventions for Mental Disorders (R01) Apply for RFA MH 16 425 Funding Number: RFA MH 16 425 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implementing a National Framework to Eliminate Mother to Child HIV Transmission in the United States Apply for CDC RFA PS12 120604CONT15 Funding Number: CDC RFA PS12 120604CONT15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Domestic Laboratory Biosafety for Ebola and other Highly Infectious Diseases Apply for CDC RFA OE15 1504 Funding Number: CDC RFA OE15 1504 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Health Department Demonstration Projects for Comprehensive Prevention, Care, Behavioral Health, and Social Services for Men Who Have Sex with Men of Color at Risk for and Living with HIV Infection Apply for CDC RFA PS15 1509 Funding Number: CDC RFA PS15 1509 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,333,333 |
| NIAMS Clinical Trial Planning Cooperative Agreement (U34) Apply for PAR 15 166 Funding Number: PAR 15 166 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Preventive Medicine Residency with Integrative Health Care Training Program Apply for HRSA 15 143 Funding Number: HRSA 15 143 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Health Department Demonstration Projects to Reduce HIV Infections and Improve Engagement in HIV Medical Care among Men Who Have Sex with Men (MSM) and Transgender Persons Apply for CDC RFA PS15 1506 Funding Number: CDC RFA PS15 1506 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $7,000,000 |
| Training and Technical Assistance for Health Department Demonstration Projects for Comprehensive Prevention, Care, Behavioral Health, and Social Services for Men Who Have Sex with Men of Color At Risk for and Living with HIV Infection Apply for CDC RFA PS15 1510 Funding Number: CDC RFA PS15 1510 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,500,000 |
| Request for Information for RFI 674 15 RHAP 001 Apply for RFI 674 15 RHAP 001 Funding Number: RFI 674 15 RHAP 001 Agency: Agency for International Development Category: Health Funding Amount: Case Dependent |
| HIV Vaccine Research and Design (HIVRAD) Program (P01) Apply for PAR 15 164 Funding Number: PAR 15 164 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Training and Technical Assistance Cooperative Agreements (NCAs) Apply for HRSA 15 140 Funding Number: HRSA 15 140 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NIAMS Clinical Trial Implementation Cooperative Agreement (U01) Apply for PAR 15 165 Funding Number: PAR 15 165 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA GH15 1630", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.